Occupancy data for PD-L1 therapeutics, reported in only a limited number of trials, are obtained using peripheral blood mononuclear cells (PBMCs) [167], and occupancy at the tumor is almost always predicted by in silico modeling. This evidence concerns the gene CD274 and neoplasm.